Abu Dhabi Startup Ecosystem: What Founders Need to Scale
For Archireef, Vivan Therapeutics, and Inovat, Abu Dhabi offered more than access to capital. Their experiences show how the Abu Dhabi startup ecosystem combines regulation, infrastructure, institutional support, talent, and commercial relationships to help foreign startups move from ambition to execution.
The pattern matters because each company operates in a different industry. Archireef works in nature tech, Vivan Therapeutics in biotech, and Inovat in fintech infrastructure. Yet all three found that choosing a base involved more than incorporating a company or raising money.
What the Abu Dhabi startup ecosystem offers beyond funding
The Global Startup Ecosystem Report 2026 ranked Abu Dhabi among the world’s Top 50 emerging startup ecosystems. The report placed the emirate in the #41-50 range globally, up from #51-60 the previous year, and valued its ecosystem at US$73.4 billion.
Its ecosystem value increased by 3,057% over the H2 2023–2025 baseline period, with growth across AI, fintech, climate tech, Web3, and digital assets.
Rankings, however, do not explain why a founder chooses one location over another. The three companies’ journeys point to a more practical set of considerations: access to relevant infrastructure, a clear route through regulation, connections with institutional partners, and the ability to reach customers and decision-makers.
Abu Dhabi enables 100% foreign ownership for many mainland business activities and in its free zones. Its strategic priorities also include economic diversification. Platforms such as Hub71 connect technology startups with funding, incentives, mentorship, and a wider network.
Archireef: nature tech needs policy and live projects
Archireef was co-founded in Hong Kong in 2020 by Vriko Yu, its CEO, and Deniz Tekerek, its CCO. The nature-tech company integrates eco-engineering with coastal infrastructure to support marine biodiversity restoration. It established its Abu Dhabi base in 2022 and has since expanded into Singapore and Saudi Arabia.
For Archireef, the value of Abu Dhabi was the proximity between public institutions, private stakeholders, infrastructure budgets, environmental regulation, and capital. The company entered the emirate with support from ADQ and Hub71, while early engagement with the Environment Agency – Abu Dhabi helped it approach the market with greater confidence.
That institutional alignment also created a route to deployment. A partnership between the Environment Agency – Abu Dhabi and Archireef advances coral reef restoration and marine biodiversity protection in Abu Dhabi using 3D-printed eco-engineering solutions.
The company secured industrial and commercial licences, established its eco-engineering factory at Khalifa Economic Zones Abu Dhabi, and set up its operational headquarters at Abu Dhabi Global Market. This enabled local manufacturing and gave Archireef access to Abu Dhabi’s industrial talent base.
The lesson for nature-tech founders is specific: capital and licences are necessary, but they do not replace access to projects and customers that incorporate ecological performance from the outset. For companies working across infrastructure and sustainability, the relevant question is whether policy can connect to deployment.
Vivan Therapeutics: deep tech needs clinical access
Vivan Therapeutics, a UK-headquartered biotech company founded and led by Laura Towart, focuses on cancer treatment through personalized drug combinations targeted to an individual’s tumor genetics. Towart had lived and worked in the GCC for six years from 2011, giving her familiarity with the market and an established network.
The company’s decision to build in Abu Dhabi was also shaped by Hub71, which provided investment and on-the-ground support. Towart identified a clear regulatory pathway through the Department of Health, clinical partners, and access to capital as important parts of the environment for a deep-tech health company.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
Vivan established its regional entity at ADGM in 2025. It is launching TuMatch, an AI-powered clinical decision-support engine designed to identify potential treatment options for cancer patients. The platform is intended to support clinicians, pharmaceutical companies, and patients seeking more tailored treatment options.
As part of its Abu Dhabi presence, Vivan collaborated with Burjeel Cancer Institute on a prospective clinical registration study for TuMatch focused on personalized colorectal cancer treatment guidance. The company has also opened discussions with local providers, including Cleveland Clinic, as it develops its regional sales.
Vivan is seeking growth funding to establish a robotics-driven research and development center in Masdar City. The planned center would generate local datasets across cancer, diabetes, and other genetic diseases to inform future drug development. Discussions are underway with sovereign wealth funds.
For Vivan, the ecosystem question is not simply whether capital is available. It is whether a company can connect clinical infrastructure, research capacity, regulatory processes, computing expertise, and institutional partners. The proposed local R&D center is intended to deepen those connections while supporting the company’s clinical and commercial expansion.
Inovat: regulated fintech needs relationships and evidence
Inovat was founded in London by Ilya Melkumov, Sofiia Baranova, and Igor Titov. Its platform enables banks, insurers, and travel companies to offer digital VAT refunds to international travelers. In 2023, the company established its base in Abu Dhabi and raised its first financing round there.
Because Inovat operates across fintech, travel, and tax infrastructure, its entry required careful planning around corporate structure, licensing, and regulatory responsibilities. Hub71 helped the company build connections with investors, banks, potential partners, and professional advisers.
Abu Dhabi also serves as a base between Europe and Asia, which is relevant to Inovat’s work with financial institutions and travelers across both regions. The company’s most accessible capital sources have been venture funds, strategic investors, and family offices that understand fintech infrastructure.
But Inovat’s experience also shows the limits of ecosystem support. Fundraising still requires patience and evidence of execution. For the company, live operations, financial-institution partnerships, measurable transaction volumes, sound unit economics, and a credible regulatory strategy have been essential to building investor confidence.
Inovat aims to expand its banking and fintech partnerships across the GCC while continuing to scale in Europe and Asia. Its plan is to integrate its VAT-refund infrastructure directly into banking, insurance, and travel platforms so travelers can access the service through providers they already use.
The practical decision for foreign founders
The three companies point to the same conclusion from different directions: Abu Dhabi is most useful when a startup needs ecosystem components that funding alone cannot provide.
- Nature tech: Archireef needed access to coastal infrastructure, environmental institutions, industrial talent, and live projects.
- Biotech: Vivan needed clinical partners, research infrastructure, regulatory support, and access to local datasets.
- Fintech: Inovat needed relationships with banks, investors, advisers, and stakeholders across regulated markets.
For founders considering the move, the implication is straightforward. Abu Dhabi should not be evaluated only as a place to incorporate or raise capital. The stronger test is whether the company can identify the institutions, customers, technical resources, and regulatory relationships required to execute its next stage.
That requires preparation. Inovat’s co-founder advises founders to understand how their business contributes to Abu Dhabi’s strategic priorities, arrive with evidence that the product works, be precise about the support they need, and remain realistic about the time required for regulated partnerships and enterprise sales.
The three journeys suggest that Abu Dhabi’s appeal lies in the alignment between a company’s operating needs and the institutions around it. For startups building in nature tech, biotech, and fintech, that alignment can determine whether a regional base becomes an administrative address or a platform for commercial growth.
More in Gulf
